<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372773</url>
  </required_header>
  <id_info>
    <org_study_id>14-007532</org_study_id>
    <secondary_id>U01AG045390</secondary_id>
    <nct_id>NCT02372773</nct_id>
  </id_info>
  <brief_title>Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects</brief_title>
  <acronym>LEFFTDS</acronym>
  <official_title>Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to learn more about normal thinking and behavior, mild thinking and
      behavior problems, Frontotemporal Dementia and other forms of dementia in families in which
      one or more relatives have a mutation associated with Frontotemporal Dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study will enroll 300 members of familial Frontotemporal Dementia (FTD)
      families across 8 experienced FTD research centers with a known mutation in MAPT, PGRN, or
      C9ORF72 (100 mutation carriers with mild dementia or minimally symptomatic yet non-demented,
      100 asymptomatic mutation carriers, and 100 clinically normal relatives who are non-mutation
      carriers) to obtain annual assessments including T1-MRI, FLAIR, diffusion tensor imaging
      (DTI), ASL perfusion (ASLp), intrinsic connectivity functional MRI (icfMRI), MR spectroscopy
      (MRS), CSF, blood, and behavioral, neuropsychological and functional assessment, for a total
      of three assessments per participant.

      A primary goal of this study is to identify the most robust and reliable methods to track
      disease progression in familial FTD so that disease-modifying therapeutic trials can be
      designed appropriately.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the symptomatic phase of familial FTD</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the asymptomatic phase of familial FTD</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of novel imaging and clinical measures for characterizing asymptomatic familial FTD subjects, and factors predicting clinical rates of progression in each group.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic and biofluid factors that modify rates of clinical and neuroimaging decline in the asymptomatic and symptomatic phases of familial FTD.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Familial Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Frontotemporal Dementia - MAPT</arm_group_label>
    <description>Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal Dementia - PGRN</arm_group_label>
    <description>Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal Dementia - C9OR72</arm_group_label>
    <description>Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood - DNA, Plasma, Serum, Peripheral blood mononuclear cells, RNA, Cerebrospinal Fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Have a mutation, or be a relative of an individual with a mutation, in one of the three
        most common genes associated with Frontotemporal Dementia - microtubule associated protein
        tau (MAPT), progranulin (PGRN; also known as granulin or GRN), or chromosome 9 open reading
        frame 72 (C9ORF72).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be a member of family with a known mutation in one of the three major FTLD
             related genes: MAPT, PGRN, or C9ORF72.

          2. At least 18 years of age.

          3. The predominant phenotype in the kindred must be cognitive/behavioral (ie, kindreds in
             whom parkinsonism or ALS is the predominant clinical phenotype among affected
             relatives may be excluded)

          4. Have a reliable informant who personally speaks with or sees that subject at least
             weekly.

          5. Subject is sufficiently fluent in English to complete all measures

          6. Subject must be willing and able to consent to the protocol and undergo yearly
             evaluations over 3 years.

          7. Subject must be willing and able to undergo neuropsychological testing (at least at
             baseline visit).

          8. Subject must have no contraindication to MRI imaging.

        Exclusion Criteria

          1. Known presence of a structural brain lesion (e.g. tumor, cortical infarct).

          2. Presence of another neurologic disorder which could impact findings (eg, multiple
             sclerosis).

          3. Subject is unwilling to return for follow-up yearly, undergo neuropsychological
             testing and MR imaging.

          4. Subject has no reliable informant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Boeve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Forsberg, Ph.D.</last_name>
    <phone>507-293-5551</phone>
    <email>forsberg.leah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josie Williams</last_name>
    <phone>507-293-5354</phone>
    <email>williams.josie@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco, Memory and Aging Center, Department of Neurology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reilly Dever</last_name>
      <phone>415-476-0670</phone>
      <email>reilly.dever@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Haley</last_name>
      <phone>904-953-9680</phone>
      <email>Haley.Dana@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neill Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Krivensky</last_name>
      <phone>617-726-6205</phone>
      <email>skrivensky@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Lucente</last_name>
      <email>DLUCENTE@PARTNERS.ORG</email>
    </contact_backup>
    <investigator>
      <last_name>Bradford Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Forsberg, PhD</last_name>
      <phone>507-293-5551</phone>
      <email>Forsberg.Leah@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deb Gearhart</last_name>
      <phone>507-293-5011</phone>
      <email>RSTLEFFTDSMANAGEMENT@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Boeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Jones</last_name>
      <phone>314-362-8420</phone>
      <email>jonesly@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nupur Ghoshal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masood Manoochehri</last_name>
      <email>mm2626@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerisity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Bove</last_name>
      <phone>215-349-5873</phone>
      <email>Jessica.Bove@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katya Rascovsky, PhD</last_name>
      <email>katyaras@mail.med.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Murray Gossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pheth Sengdy</last_name>
      <phone>604 822 7989</phone>
      <email>Pheth.Sengdy@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Ging-Yeuk Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Mackenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bradley Boeve</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Frontotemporal Dementia</keyword>
  <keyword>MAPT</keyword>
  <keyword>PGRN</keyword>
  <keyword>C9ORF72</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data can be shared following a formal request and approval by the executive committee overseeing the protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

